The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Eunice WangDuring the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the AML Hub spoke to Eunice Wang, Roswell Park Comprehensive Cancer Center, Buffalo, US, about the rapidly changing treatment landscape for patients with AML.
Staying on track in a rapidly changing treatment landscape
A number of exciting advances have been made in treatment approaches to AML over the past few years. Firstly, the phase III VIALE-A study, established venetoclax + azacitadine as a superior front-line induction treatment for elderly or unfit patients with AML. Furthermore, the oral hypomethylating agent, CC-486, became the first FDA approved maintenance strategy for AML.
The outlook for patients with P53 mutant AML has also improved. Two targeted therapies, APR-246 and magrolimab, have demonstrated encouraging response rates in this setting; a major advance in the treatment approach for patients with P53 mutant AML.
Eunice Wang concludes by outlining promising immunotherapeutic approaches to AML, including the CD33/CD3 bispecific antibody, AMG 330.
Your opinion matters
Approximately what proportion of your patients with FLT3-mutations also have NPM1 and DNMT3A co-mutations?